Dr. Weitzman on Sequencing Challenges in Myeloma Treatment

James Weitzman, MD, medical oncologist, Emerson Hospital and Waltham Cancer Center of Massachusetts General Cancer Center, discusses sequencing challenges in multiple myeloma treatment.

It is an amazing time for patients with multiple myeloma because so many options are available, says Weitzman. However, with these advances come new challenges because now the field is trying to stay ahead of the data that are rapidly being reported and stay caught up with the guidelines on how to best use these agents.

It is important to stay a step ahead in order to provide patients with the best treatment possible, says Weitzman. Some questions that arise include: What agents should be used in the frontline setting? How can they be combined? Upon relapse, should patients be treated immediately or should they wait for symptomatic relapse? What agents should be used and when can they be reused? What agents combined with each other can have synergy? These are challenging yet exciting questions, says Weitzman. The field is constantly learning and discovering new ways to improve outcomes for patients with multiple myeloma, concludes Weitzman.